November 16, 2016 - By Marie Mckinney · 0 Comments
Genvec Inc (NASDAQ:GNVC) institutional sentiment increased to 1.8 in 2016 Q2. Its up 1.13, from 0.67 in 2016Q1. The ratio increased, as 9 funds opened new and increased positions, while 5 decreased and sold their stakes in Genvec Inc. The funds in our partner’s database now have: 6.08 million shares, up from 3.18 million shares in 2016Q1. Also, the number of funds holding Genvec Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 2 Increased: 6 New Position: 3.
GenVec, Inc. is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The company has a market cap of $9.32 million. The Firm designs, tests and makes adenoviral product candidates. It currently has negative earnings. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.
About 39,252 shares traded hands. GenVec Inc (NASDAQ:GNVC) has declined 51.90% since April 14, 2016 and is downtrending. It has underperformed by 56.59% the S&P500.
According to Zacks Investment Research, “GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company’s product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease.”
Perceptive Advisors Llc holds 0.24% of its portfolio in GenVec Inc for 606,644 shares. Frigate Ventures Lp owns 1.22 million shares or 0.13% of their US portfolio. Moreover, Cormorant Asset Management Llc has 0.1% invested in the company for 1.19 million shares. The New Jersey-based Sabby Management Llc has invested 0.05% in the stock. Dafna Capital Management Llc, a California-based fund reported 95,800 shares.#img1#
Ratings analysis reveals 100% of Genvec’s analysts are positive. Out of 2 Wall Street analysts rating Genvec, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $2.30 while the high is $5. The stock’s average target of $3.65 is 828.75% above today’s ($0.393) share price. GNVC was included in 2 notes of analysts from March 10, 2016. Rodman & Renshaw reinitiated GenVec Inc (NASDAQ:GNVC) on Monday, June 20 with “Buy” rating. The firm has “Buy” rating given on Thursday, March 10 by H.C. Wainwright.
GenVec, Inc. (GenVec), incorporated on December 7, 1992, is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Firm designs, tests and makes adenoviral product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Firm develops and commercializes its product candidates through collaborations.
More notable recent GenVec Inc (NASDAQ:GNVC) news were published by: Marketwatch.com which released: “GenVec Inc.” on December 21, 2009, also Prnewswire.com with their article: “GenVec Reports Third Quarter 2016 Financial Results” published on November 04, 2016, Quotes.Wsj.com published: “News GenVec Inc.GNVC” on February 02, 2011. More interesting news about GenVec Inc (NASDAQ:GNVC) were released by: Prnewswire.com and their article: “GenVec To Present At 2016 Cell & Gene Meeting On The Mesa” published on September 28, 2016 as well as Prnewswire.com‘s news article titled: “GenVec and TheraBiologics form Collaboration to Develop Neural Stem Cell …” with publication date: March 23, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marie Mckinney